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Abstract
Background: Although the activation of dermal dendritic cells (DCs) or Langerhans cells (LCs) via p38 mitogen-activated
protein kinase (MAPK) plays a crucial role in the pathogenesis of metal allergy, the in vivo molecular mechanisms have not
been identified and a possible therapeutic strategy using the control of dermal DCs or LCs has not been established. In this
study, we focused on dermal DCs to define the in vivo mechanisms of metal allergy pathogenesis in a mouse nickel (Ni)
allergy model. The effects of DC therapy on Ni allergic responses were also investigated.
Methods and Finding: The activation of dermal DCs via p38 MAPK triggered a T cell-mediated allergic immune response in
this model. In the MAPK signaling cascade in DCs, Ni potently phosphorylated MAP kinase kinase 6 (MKK6) following
increased DC activation. Ni-stimulated DCs could prime T cell activation to induce Ni allergy. Interestingly, when MKK6 gene-
transfected DCs were transferred into the model mice, a more pronounced allergic reaction was observed. In addition,
injection of short interfering (si) RNA targeting the MKK6 gene protected against a hypersensitivity reaction after Ni
immunization. The cooperative action between T cell activation and MKK6-mediated DC activation by Ni played an
important role in the development of Ni allergy.
Conclusions: DC activation by Ni played an important role in the development of Ni allergy. Manipulating the MKK6 gene in
DCs may be a good therapeutic strategy for dermal Ni allergy.
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Introduction
Metal allergy is an inflammatory disease categorized as a
delayed-type hypersensitivity (DTH) reaction, similar to contact
dermatitis and eczema [1,2]. This skin disease is induced by a
complex process involving immune responses of numerous cell
types, and cooperation among these cells is crucial for symptom
development [3,4].
Among various metals, nickel (Ni), when used in costume
jewelry or dental alloys, is the most frequent cause of contact
allergy [5–7]. Ni-specific T cell responses are crucial for the
development of allergies in human and mouse models [8–10].
However, it is unclear how T cells recognize Ni presented to them
by antigen-presenting cells (APCs). In the skin, Langerhans cells
(LCs) or dermal dendritic cells (DCs) play fundamental roles as
APCs for uptake, processing, and presentation of antigens [11,12].
Although there is no evidence that DCs or LCs can directly clear
Ni, these APCs may contribute to a Ni allergic response via other
molecular mechanisms.
Ni ions (Ni
2+) are known to be released from various alloys into
the skin and exert proinflammatory and irritant properties as
potent allergens or haptens [13,14]. Ni penetrates the skin where it
may associate with epithelial cells or become attached to MHC
molecules on LCs or DCs. APCs are activated by certain cytokines
such as IL-1b and TNF-a produced by keratinocytes. The
cytokines regulate the expression of E-cadherin and chemokines
like matrix metalloproteinase (MMP)-9, secondary lymphoid tissue
chemokine (SLC), and MIP-3b produced by the APCs [15–18].
Subsequently, APCs migrate to draining lymph nodes where they
present haptens to naı ¨ve T cells. Re-exposure to the same hapten
leads to a hypersensitivity reaction in an effector phase.
Recent in vitro experiments have reported that contact sensitizers
likeNi activate epidermalDCsor LCs as shown by the upregulation
of CD80, CD83, CD86, and MHC class II [19]. Moreover, in vitro
experiments using human DCs showed that Ni-induced phosphor-
ylationof p38mitogen-activated protein kinase (MAPK) was critical
for the maturation of immature DCs [20–22]. In addition, the
conditional induction of a dominant active form of MAP kinase
kinase 6 (MKK6) efficiently induced the activation of human LCs
[23]. However, it remains uncertain whether the in vivo activation of
DCs in the skin is induced by Ni via the MAPK signaling pathway.
Furthermore, it is unclear whether the signaling pathway of DCs
stimulated by Ni is different from that of the other stimuli with
regard to signal strength or the pathway itself.
PLoS ONE | www.plosone.org 1 April 2011 | Volume 6 | Issue 4 | e19017The aim of this study was to determine the signaling pathway
for APC activation in dermal immune responses related to the
pathogenesis of Ni allergy in a mouse model. In addition, a
therapeutic strategy based on the in vivo molecular mechanisms of
Ni allergy was applied to this model.
Results
Induction of Hypersensitive Reactions to NiCl2
To induce hypersensitive reactions to Ni, Ni is typically applied
to the skin surface as a secondary challenge after sensitization. In
the first series of experiments, we evaluated results of the mouse
ear swelling test, as described previously [24]. Using this protocol
(Figure 1A), we found flare reactions and slight increases in ear
swelling in response to NiCl2 (Figure 1B).
In order to elucidate the symptoms associated with hypersen-
sitive reactions to NiCl2, we administered intradermal injections
into the ear pinnae of mice as previously described [25]. Although
attempts to induce Ni allergy in mice have often failed, a DTH
reaction to Ni has been achieved after injecting NiCl2 in
combination with an adjuvant or irritant [25]. Thus, we attempted
to induce DTH by injecting NiCl2 in combination with either
incomplete Freund’s adjuvant (IFA) or complete Freund’s
adjuvant (CFA) (Figure 1C). A DTH reaction to NiCl2 was
induced in C57BL/6 (B6) female mice using the method shown in
Figure 1C.
Briefly, NiCl2 with IFA was intraperitoneally injected into B6
mice for initial immunization. Two weeks later, NiCl2 together
with CFA was intradermally injected into the ear skin for a recall
immune response. DTH reactions were determined by measuring
the changes in ear thickness 48 hours after the challenge.
Although increased ear thickness of Ni-treated mice after
injection of Ni with IFA has been previously reported [25], in this
study, ear swelling was only around 0.2 to 0.3 mm (Figure 1D). In
contrast, the ear thickness of Ni+CFA-treated mice after Ni with
IFA was significantly higher compared with that of CFA-treated
and other mice (Figure 1D). Redness and swelling of the ear skin
was observed in Ni+CFA-treated mice after Ni with IFA
(Figure 1E). Histological examination of the ear epidermis of
Ni+CFA-treated mice after Ni with IFA showed edema,
congestion, and extensive infiltration of inflammatory cells,
including mononuclear cells, monocytes, neutrophils, and macro-
phages, in the connective and muscular tissues; however, there was
no inflammation in control ears (Figure 1F, Figure S1A). In
addition, toluidine blue-positive cells, including degranulated mast
cells, found in the lesions of Ni allergy mice were significantly
increased compared with those in control mice (Figure S1B). This
Ni allergy model with severe inflammation was used to analyze the
cellular mechanisms and to develop a therapeutic strategy.
Cellular Mechanisms of Ni Allergy
To characterize Ni allergy, immune responses to another
antigen or metal were compared with Ni immune responses in the
present allergy model. Briefly, NiCl2 or the control metal/antigen
(PBS, ovalbumin [OVA], or TiO2 [Ti]), along with IFA, was
intraperitoneally injected into B6 mice. Titanium has been known
as one of biocompatible metals, and so it is believed that the
allergic sensitivity induced by nickel is rarely occurred by titanium
[26]. Therefore, titanium was used as a control metal in this study.
Two weeks later, NiCl2 or the abovementioned control metal/
antigen, along with CFA, was intradermally injected into the mice.
At 24 and 48 hours after immunization, DTH reactions were
assessed by measuring ear thicknesses. In contrast to the swelling
seen in OVA- or Ti-treated mice, the ear thicknesses of Ni-treated
mice were significantly increased at both 24 and 48 hours after the
second challenge (Figure 2A).
Flow cytometry was performed to identify the phenotypes of
infiltrating lymphocytes in the allergic lesions. Large numbers of
CD3
+ T cells and CD19
+ B cells were detected in the tissue
samples obtained from NiCl2-injected mice (Figure 2B). In
addition, immunohistochemical analysis indicated that a much
higher proportion of CD3
+ T cells were observed in the skin tissues
of NiCl2-injected mice, compared with CD19
+B cells (Figure 2C).
The infiltrating T cells were largely CD4
+ T cells, with small
numbers of CD8
+ T cells and NK1.1
+ natural killer (NK) cells
(Figure S2A). Moreover, the proportion of NKT cells reactive to
anti-a-GalCer-CD1d complex in the ear tissues of NiCl2-injected
mice was significantly increased compared with that of control
mice (Figure S2B). The number of MHC class II
+CD11c
+ dermal
DCs was significantly higher in NiCl2-injected mice than in
control mice (Figure 2D). In addition, the absolute numbers of
dermal DCs in NiCl2-injected mice were significantly increased
compared with those in control mice (Figure 2E). In contrast, the
number of DCs in the cervical lymph nodes of Ni-injected mice
was not increased (Figure S2C). These results suggest that T cells
and dermal DCs in the skin lesions play important roles in the
development of the hypersensitivity reaction induced by NiCl2.
Activation of DCs by NiCl2 via MAPK
Numerous signaling molecules control the maintenance of DCs
in peripheral tissues [27]. Among these, MAPK is known to be a
key signal transducer for the activation of DCs in various immune
responses [28,29]. Regarding DCs in allergic reactions in humans,
p38/MKK6 in the MAPK pathway plays a significant role in the
activation of DCs during the development of skin allergy [23].
Thus, we focused on p38/MKK6 of DCs in mice. To define in vivo
p38/MKK6 activation of dermal DCs in our Ni allergy model,
Western blot analysis of MKK6 was performed using skin tissue
samples. MKK6 phosphorylation was significantly increased in the
skin tissues of NiCl2-injected mice (Figure 3A), but absent in the
skin tissues of PBS-, OVA-, and TiO2-injected mice (Figure 3A).
Further, phospho-MKK6 was detected in MHC class II
+ DCs in
the skin tissues of NiCl2-injected mice (Figure 3B). These results
showed that dermal DC activation via MKK6 was important for
the pathogenesis of Ni allergy in the skin.
On the other hand, when phosphorylation of MKK6 and p38
in bone marrow-derived cells (BMDCs) stimulated with NiCl2 was
examined by Western blot analysis, the phosphorylated levels of
MKK6 and p38 in NiCl2-stimulated BMDCs were elevated
similar to those in LPS-stimulated BMDCs (Figure S3A). When
stimulated with TiO2, however, no phosphorylation of MKK6
and p38 was detected (Figure S3A). We used real-time PCR to
examine the MKK6 mRNA expression in BMDCs stimulated
with NiCl2. The mRNA expression level of MKK6 in BMDCs
stimulated with NiCl2 was increased in a time-dependent manner;
it was much higher than that in LPS-stimulated BMDCs during
the first 24 hours (Figure S3B), but decreased after 36 hours
(Figure S3B). These results showed that Ni could directly trigger
the activation of DCs via p38/MKK6 to induce an allergic
immune reaction.
Enhanced Allergy after Transfer of T Cells Primed by
NiCl2-stimulated DCs
As shown in Figure 2, a large number of T cells had infiltrated
into the lesions of inflamed skin tissues. In addition, when purified
T cells from the lymph nodes of the Ni allergy model were
stimulated with anti-CD3 mAb, production of Th1-type cytokines,
including IL-2 and IFN- c, was significantly increased compared
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PLoS ONE | www.plosone.org 2 April 2011 | Volume 6 | Issue 4 | e19017Figure 1. Induction of Ni allergy. (A) Protocol for inducing the Ni allergy model. First, an intraperitoneal injection of NiCl2 with or without IFA was
administered. After 2 weeks, an ointment (o) of NiCl2 with Vaseline was applied to the ear pinnae as a secondary challenge. (B) DTH was assessed by
measuring the ear thickness at 48 hours after the last challenge. Results are means 6 SD for 4 mice in each group. (C) Protocol for inducing a Ni
allergy model. First, an intraperitoneal injection of NiCl2 with or without IFA was administered. Then, after 2 weeks, an intradermal injection of NiCl2
with or without CFA was administered to the ear pinnae to induce a secondary reaction. (D) DTH was assessed by measuring the ear thickness at
48 hours after the last challenge. Results are means 6 SD for 4 to 6 mice in each group. **P,0.005. (E) Representative photos of the ears from control
and NiCl2-injected mice. (F) Histological images of inflammatory lesions in the skin are representative of 5 mice in each group.
doi:10.1371/journal.pone.0019017.g001
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of Th2-type cytokines such as IL-4 and IL-10 from anti-CD3
mAb-stimulated T cells of Ni allergy model was similar to that of
the other control mice (Figure S4). These findings suggest that T
cells play a key role as effector cells in the pathogenesis of Ni
allergy. However, it was still unclear how Ni-stimulated DCs were
related to T cell responses in allergic reactions.
Thus, T cells purified from the spleens of normal B6 mice were
co-cultured with Ni-stimulated BMDCs in vitro for 24 hours. Then,
the resulting primed T cells were transferred intraperitoneally into
normal B6 mice, and 2 weeks later, NiCl2 with CFA was injected
intradermally to induce DTH (Figure 4A). The skin thickness of
the model mice with transferred Ni-BMDCs-stimulated T cells was
significantly increased compared with that of mice with transferred
nonstimulated T cells (Figure 4B). Pathological examination of the
skin lesions in the mice with transferred Ni-BMDCs-stimulated T
cells showed more severe inflammation, including lymphocyte
infiltration, edema, and congestion, compared with those in the
mice with transferred nonstimulated T cells (Figure 4C). These
results suggested that the T cells primed by Ni-stimulated DCs
were important for the onset of Ni allergy.
Effects of Overexpression of MKK6 in DCs on Ni Allergy
To examine whether DCs activated by the engagement of p38/
MKK6 signaling influenced the development of skin allergy,
BMDCs were transfected with the MKK6 gene (MKK6-DC) and
stimulated with NiCl2 for 48 hours. Then, MKK6-DCs were
subcutaneously transferred into normal B6 mice, and 2 weeks
later, NiCl2 was intradermally injected to induce Ni allergy
(Figure 5A). The skin redness in MKK6-DC-transferred mice was
Figure 2. Characteristics of the Ni allergy model. (A) DTH was evaluated by measuring the ear thickness of the treated mice. Results are means
6 SD for 5 mice in each group. *P,0.05. (B) T and B cell populations of purified lymphocytes from skin tissues were analyzed by flow cytometry.
Representative results of 5 mice in each group are shown. (C) Immunohistochemical analysis of T and B cells was performed on frozen sections of
inflamed ear tissues obtained from Ni allergy mice. Representative photos of 2 independent experiments are shown. (D) Dermal DCs were detected
by flow cytometry. These results represent 2 independent experiments with 3 mice in each group. (E) The absolute numbers of dermal DCs were
determined. *P,0.05.
doi:10.1371/journal.pone.0019017.g002
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( F i g u r e5 B ) .I na d d i t i o n ,p a t h o logical examination revealed
remarkable infiltration of immune cells along with congestion
and edema in the skin lesions of MKK6-DC-transferred mice
(Figure 5C). Significantly enhanced ear swelling was detected
within 48 hours of injecting NiCl2 into MKK6-DC-transferred
mice compared with Mock-DC-transferred mice (Figure 5D). In
addition, we investigated production of cytokines by Ni-
stimulated DCs that are required for T cell priming, including
IL-12, IFN-c, and IL-10. The amounts of IL-12, IFN-c,a n dI L -
10 produced by BMDCs after stimulation with NiCl2 were equal
to those after stimulation with LP S( F i g u r eS 5 ) ,a n dt h ec y t o k i n e
production by NiCl2-stimulated BMDCs were significantly
higher compared with that by TiO2-stimulated BMDCs (Figure
S5). These results suggested that Ni-mediated DC activation
played a central role in T cell priming for the onset and
development of Ni allergy.
Effective Therapy for Ni Allergy using MKK6 siRNA
We next tested a therapeutic strategy for Ni allergy using short
interfering (si) RNA targeting the MKK6 gene. Before inducing a
DTH reaction, MKK6 siRNA with atelocollagen as an in vivo gene
delivery system was subcutaneously injected into the ear skin of the
model mice. Ear thickness was measured at 48 hours after
injecting NiCl2 or saline control (Figure 6A). We confirmed that
the MKK6 mRNA level in siRNA-treated DCs was significantly
reduced (,1/6) compared with that in control siRNA-treated DCs
(data not shown).
Ear thickness of MKK6 siRNA-treated allergy model mice was
significantly reduced compared with those of control siRNA-
treated mice (Figure 6B). In addition, pathological examination
showed no detectable inflammatory lesions in MKK6 siRNA-
treated mice, while severe inflammation with extensive lympho-
cytic infiltration, edema, and congestion was observed in the
lesions of the mice injected with control siRNA (Figure 6C).
Further, although phosphorylation of MKK6 of MHC class II
+
dermal DCs in the skin sheets from MKK6 siRNA-treated mice
was nearly undetectable, there was phosphorylation in the sheets
from control siRNA-treated mice (Figure 6D). This showed that an
effective therapy using siRNA targeting the MKK6 gene could be
used for treating Ni allergy.
Discussion
DCs in the epidermis and dermis participate in the recognition
of pathogens. The two major populations of DCs present in
normal skin are epidermal LCs and dermal DCs. These DCs
function as APCs and play key roles in sensing pathogens and
initiating allergic responses. Immature DCs, such as epidermal
LCs, reside in the peripheral tissues. When these DCs are
activated by antigens and mature, they migrate from peripheral
sites to lymphoid organs where they stimulate T cells to induce an
immune response [11,30]. The cutaneous immune system depends
on multiple cell-cell contacts for antigen recognition and
presentation, as well as inflammation. LCs facilitate the develop-
ment of contact hypersensitivity responses by efficiently presenting
haptens to T cells [31]. However, it has been suggested that
dermal DCs can support LC functions [31].
From our results and those of other studies, allergy symptoms,
such as swelling and flare reactions, were minimal and transient
after applying a Ni-based ointment to the skin surface. Artik et al.
demonstrated contact hypersensitivity in model mice after
intradermally injecting Ni into the ear pinnae [25]. Our method
using intradermal injections of Ni with CFA in a new DTH model
was based on their report. Clinical skin tests (such as puncture tests
and intradermal injection tests) along with patch tests have been
used for the diagnosis of metal allergy. Therefore, we injected
NiCl2 with CFA intradermally into mice in order to obtain clear
hypersensitivity responses.
p38 MAPK is an evolutionarily highly conserved stress response
pathway in various cells [32]. p38 MAPK is activated by an
upstream kinase (MKK6 or MKK3) and then translocated into the
nucleus where target molecules are phosphorylated by p38 MAPK
[33,34]. A previous report showed that activation of human LCs
was triggered by MKK6 [23]. In addition, several reports using in
vitro experiments showed that p38 MAPK phosphorylation played
an important role in the activation of DCs by Ni [34–36]. Our
experiments using a Ni allergy model strongly suggest that MKK6
phosphorylation in dermal DCs is the first important trigger for
the onset of an allergic response to Ni.
Ni is the most frequent cause of metal allergy. It is possible that
Ni in the skin may interact with proteins, after which dermal DCs
capture the Ni–antigen complex. At this stage, Ni might be a
potent factor for triggering activation of DCs via MKK6. In our
model, the specific activation of MKK6 in DCs was observed only
when the cells were stimulated with Ni but not another metal or
antigen such as Ti or OVA. However, because the phosphory-
lation of MKK6 in DCs was detectable after stimulation with LPS
in vitro, the signaling pathway induced by Ni could be modulated
by other stimuli. In addition, we could not identify the mechanism
by which Ni modulated MKK6 expression.
Figure 3. DC activation by Ni via MKK6. (A) Phosphorylation of
MKK6 in the inflamed tissues of the Ni allergy model was analyzed by
Western blot analysis. GAPDH was used as the internal control. (B)
Phosphorylation of MKK6 (Red) of MHC class II
+ (Green) dermal DCs
from Ni allergy mice was detected by confocal microscopy. These
results represent 2 independent experiments with 3 to 5 mice in each
group.
doi:10.1371/journal.pone.0019017.g003
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plays a crucial role in the development of contact allergy to Ni [37]
and that only TLR4-deficient mice expressing transgenic human
TLR4 developed contact hypersensitivity to Ni, while animals
expressing mouse TLR4 did not develop DTH. Although the cell
type contributing to a TLR4-mediated allergic reaction was not
identified, immune cells such as DCs, macrophages, and
endothelial cells were associated with an allergic reaction to Ni
via TLR4. It is possible that TLRs other than TLR4 are related to
Ni allergy in mice. In our mouse model, although the signaling
pathway via TLR in DCs was not examined, MKK6 phosphor-
ylation was observed in LPS-stimulated DCs in vitro. Thus,
cooperative or synergistic actions of Ni with other signaling
pathways, including TLR, following MKK6 activation may be
associated with Ni allergy in this mouse model. Our in vivo
experiments suggested that DCs activated by Ni enhanced T cell
migration to local lesions and T cell-dependent allergic response;
however, it remains unclear how Ni can stimulate or control DC
activation via MKK6. Moreover, our result showed that
significantly increased number of NKT cells reactive to anti-
aaGalCer-CD1d complex was found in the ear lesion of Ni model
mice. CD1d-restricted NKT cells have been referred to as natural
memory cells in both innate and acquired immune responses [38].
However, the relationship between metal allergy and the role of
NTK cell has been still unidentified. Further research using our
model will be necessary for understanding the cellular mechanism
of metal allergy.
DC maturation can be initiated by inflammatory stimuli, such
as cytokines, LPS, CD40 ligation, and contact allergens [39].
Activated DCs take up antigens and produce a variety of cytokines
and chemokines, which in turn attract and activate eosinophils,
macrophages, and NK cells to the site of antigen entry [30]. After
antigen capture, DCs migrate to regional lymph nodes and present
peptide-MHC complexes to antigen-specific T cells that induce T
cell-dependent immune responses, such as Ni allergy [40].
Interestingly, our results showed a significantly increased number
of dermal DCs in the skin tissues of mice with Ni allergy. These
findings suggest that circulating precursor DCs might accumulate
at the NiCl2 injection site. Moreover, the experiments using skin
tissues demonstrated that phosphorylation of MKK6 in dermal
DCs and LCs was clearly detectable. These results indicated that
stimulation with Ni enhanced both accumulation and activation of
DCs.
DCs are activated by signaling via pattern recognition receptors
(PRRs), such as TLRs and retinoic acid-inducible gene I-like
receptors, in response to a variety of ligands [41,42]. PRR
signaling leads to the activation of nuclear factor (NF)-kB.
Although it is unclear whether Ni can interact with receptors
such as PRRs, previous reports showed that the differentiation of
human DCs is promoted by Ni via NF-kB activation [43,44]. It
Figure 4. Effect of T cell transfer on DTH in the Ni allergy model. (A) Purified T cells from the spleens of B6 mice were co-cultured with BMDCs
in the absence (control) or presence of NiCl2 for 48 hours and then intraperitoneally transferred into B6 mice. DTH reaction was induced by injecting
NiCl2. (B) Ear thickness was measured at 48 hours after the challenge. Results are means 6 SD for 5 mice in each group. *P,0.05. (C) Inflammatory
lesions of the mice with transferred Ni-DC-stimulated T cells.
doi:10.1371/journal.pone.0019017.g004
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pathogenesis of metal allergy.
Our in vivo experiments demonstrated that manipulating the
MKK6 gene of DCs could control Ni allergy. Many reports on
DC therapy for cancer or infection have indicated that antigen
presentation to T cells by DCs is important for controlling these
diseases [14,45,46]. However, there are no reports regarding
DC therapy for metal allergy. Our new approach with siRNA
targeting the MKK6 gene could be a powerful strategy for
the prevention and cure of metal allergy. Careful attention
should be paid to the therapeutic effects of MKK6 inhibition
on the immune system in the treatment of allergic immune
responses.
In conclusion, the signaling pathway via p38/MKK6 plays a
key role in activating dermal DCs in the pathogenesis of metal
allergy. DC therapy using MKK6 gene manipulation could be
effective for treating metal allergy. Characterization of this cellular
mechanism could have clinical implications by supporting the
development of new diagnoses or treatments for these allergic
diseases.
Materials and Methods
Ethics
This study was conducted according to the principles expressed
in the Declaration of Helsinki. The study was approved by the
Institutional Review Board of the University of Tokushima
(toku09021).
Mice
Female C57BL/6J mice (6–8 weeks old) were purchased from
CLEA Japan, Inc (Tokyo, Japan). All mice were maintained in
specific pathogen-free conditions in our animal facility.
Histology and Immunohistochemistry
Skin was removed from the mice, fixed with 10% phosphate-
buffered formaldehyde (pH 7.2), and prepared for histological
examination. Formalin-fixed tissue sections were stained with
hematoxylin and eosin. Immunohistochemistry was performed for
freshly frozen sections by the biotin-avidin immunoperoxidase
method using an avidin-biotin immunoperoxidase complex
reagent (Vector Laboratories, Burlingame, CA, USA). Monoclo-
nal antibodies against CD3 and CD19 (eBioscience, San Diego,
CA, USA) were used.
Induction of Ni Allergy
Ni allergy was induced using a modification of a method
described previously [24,25]. To induce a hypersensitivity
reaction to Ni, 25 mlo f1mmol/ml NiCl2 with 25 mlo fI F A
(ICN Biomedicals, Inc., Aurora, OH, USA) was intraperitone-
ally injected into B6 mice for initial immunization. Two weeks
later, mice were administered intradermal injections of Ni,
Figure 5. Effect of DC transfer on the Ni allergy reaction. (A) MKK6 DNA or mock plasmids were transfected into BMDCs. MKK6/DCs or Mock/
DCs were subcutaneously injected into B6 mice. The mice were challenged with NiCl2 to induce DTH. (B) Representative photos are shown for 3 to 5
mice in each group. (C) Inflammatory lesions of the mice with transferred MKK6/DCs. These results are representative of 2 independent experiments
with 3 mice in each group. (D) Ear thickness was measured at 48 hours after the challenge. Results are means 6 SD for 5 mice in each group. *P,0.05.
doi:10.1371/journal.pone.0019017.g005
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using 28G1/2 needles (TERUMO Tokyo, Japan) for a recall
immune response. DTH reactions were determined by
measuring the changes in ear thickness at 24 or 48 hours after
the challenge [25].
DC Preparation
DCs were prepared from freshly isolated bone marrow cells as
described previously [26]. Briefly, bone marrow cells were seeded
in 6-well culture plates (Nunc A/S, Roskilde, Denmark) in
RPMI-1640 medium supplemented with 10% heat-inactivated
FCS, 2 mM L-glutamine, 100 U/ml penicillin, and 100 mg/ml
streptomycin, and then incubated for 1 hour at 37uCi na
humidified 5% CO2 atmosphere. After nonadherent cells were
removed, adherent cells were incubated and changed to 1 ml of
fresh medium containing 10 ng/ml GM-CSF (R&D System, Inc.,
Minneapolis, MN, USA) and 1 ng/ml IL-4 (eBioscience) on days
2, 4, and 6. Dermal DCs were prepared from the skin of female
B6 mice. Excised skin was cut into small pieces and the dermal
side was exposed to 1.0% trypsin at 37uC for 60 minutes.
Epidermis was incubated in 0.025% DNase for 20 minutes at
room temperature. After an equal volume of RPMI was added,
the solution was swirled for 5 minutes and filtered using a 70 mm
cell strainer (BD Biosciences, Franklin Lakes, NJ, USA). The
dermal cell suspension that included DCs was washed three times
with RPMI, and the resulting pellet was re-suspended. Dermal
DCs were enriched by centrifugation using Opti-prep (Invitrogen,
Carlsbad, CA, USA).
Figure 6. DC therapy for Ni allergy. (A) siRNA for MKK6 with atelocollagen was subcutaneously injected into the ear skin of Ni allergy mice. (B) Ear
thickness was measured at 48 hours after injecting NiCl2. Results are means 6 SD for 5 mice in each group. *P,0.05. (C) Pathological findings after in
vivo administration of MKK6 siRNA and control siRNA. (D) Phosphorylation of MKK6 of MHC class II
+ dermal DCs was analyzed by confocal microscopy.
These results are representative of experiments with 5 mice in each group.
doi:10.1371/journal.pone.0019017.g006
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Expression levels of surface markers were examined by staining
1610
6 cells with 1 mg/ml of antibodies against CD3, CD4, CD8,
CD19, CD11c, and MHC class II conjugated with either FITC or
PE (eBioscience). Cells were analyzed on FACScan (BD
Biosciences).
Western Blot Analysis
Samples of stimulated or nonstimulated DCs were subjected to
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) with 10% acrylamide gel, transferred onto a polyvinyli-
dene fluoride (PVDF) membrane (Bio-Rad Laboratories, Hercu-
les, CA, USA), and the blotted membranes were incubated with
anti-MKK6, phospho-MKK6 (Cell Signaling Technology, Inc.,
Denver, MA, USA), or glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH) (Santa Cruz Biotechnology, Inc., Santa Cruz,
CA, USA) mAbs. Immune complexes were detected using
horseradish peroxidase (HRP)-conjugated anti-mouse IgG (Bio-
Rad Laboratories) and ECL-plus reagents (Amersham Bioscience
Corp. Piscataway, NJ, USA).
MKK6 Plasmid Construction and Transfection
MKK6 cDNA obtained from RT-PCR was subcloned into an
expression vector, pcDNA3.1 (Invitrogen). Transient transfections
were carried out using a jet-PEI Mannose reagent (Poly
transfection, Illkirch, France) before stimulation. DCs were
transfected with the MKK6 plasmid, and then stimulated with
either 1 mmol/ml NiCl2 or 1 mmol/ml TiO2 for 48 hours.
siRNA for MKK6
MKK6 and control scramble siRNA reagents were obtained from
B-bridge International, Inc. (Sunnyvale, CA, USA). Sequences of the
oligonucleotides were as follows: MKK6: sense, 59-CUACAGUA-
GUGAAGAGAUUTT-39;a n t i s e n s e ,5 9-AAUCUCUUCACUA-
CUGUAGTT-39 and control: 59-ATCCGCGCGATAGTA-
CGTA-39.U s i n gt h ein vivo siRNA transfection kit AteloGene
(KOKEN,Tokyo, Japan), siRNAwas injected intoear skin according
to the manufacturer’s instructions [47]. In brief, 10 mMs i R N Aw a s
mixed with AteloGene and rotated gentlyat 4uC for 20 minutes. This
solution (20 ml) was subcutaneously injected into the ear pinnae. Five
days after injection, ear swelling was evaluated.
Confocal Microscopic Analysis
Skin sheets were isolated from ears of treated mice with 3.8%
ammonium thiocyanate, and stained with anti-phospho-MKK6
(Santa Cruz Biotechnology) mAb and MHC class II mAb
(eBioscience). These sheets were analyzed using Confocal Laser
Microscan (LSM 5 PASCAL; Carl Zeiss. Inc., Oberkochen,
Germany).
Statistical Analysis
Results are given as means 6 standard deviations (SD).
Comparison was done using Student’s t test or Mann-Whitney U
test. Differences were considered statistically significant for P
values of ,0.05.
Supporting Information
Figure S1 Inflammatory lesions in Ni allergy model. (A) Edema
and inflammatory cell infiltrations were observed in the skin tissues
of Ni allergy mice. Photos are representative of five mice in each
group. Original magnification is 6100 (upper) and 6200 (lower).
(B) The number of toluidine blue
+ cells including mast cell in the
lesion of Ni allergy model was significantly increased compared to
that of control mice. Toluidine blue staining was performed as
described in Methods S1. Photos are representative of three mice
in each group. Data are means 6 SD of 3 mice. *P,0.05, vs
control.
(TIF)
Figure S2 Flow cytometric analysis of immune cells in Ni allergy
model. (A) CD4
+ and CD8
+ T cells or NK1.1
+ cells of ear tissues
form controls and Ni allergy models were detected by flow
cytometry. Results are representative of three mice in each group.
(B) NKT cells of spleen, cervical lymph nodes, and ear tissues were
detected by using PE-conjugated anti-a
,GalCer mAb-CD1d
complex. Results are representative of three mice in each group.
(C) CD11c
+ MHC class II
+ DCs in cervical lymph nodes (LNs)
from control, OVA, TiO2, and NiCl2-injected mice were analyzed
by flow cytometry as described in Method S1. The results were
representative of three to five mice in each group.
(TIF)
Figure S3 Activation of MAPK signaling of DCs by Ni. (A)
BMDCs were stimulated with NiCl2, LPS or TiO2 for 24 hours,
phosphorylation of MKK6 and p38, and total MKK6 and p38
protein were detected by Western blot analysis. GAPDH was used
as the respective internal control. Results are representative of 3
independent experiments.(B)MKK6mRNAexpressionofBMDCs
stimulated with NiCl2 or LPS was analyzed by real-time PCR as
described in Method S1. Data are shown as relative expressions to
b-actin, and are representative of 3 independent experiments.
(TIF)
Figure S4 Cytokine secretions from Ni-stimulated T cells. T
cells from cLNs of control, OVA, TiO2, and NiCl2-injected mice
were enriched by negative selection using mAbs (anti-MHC class
II, B220, NK1.1, and CD11b) and magnetic beads. The T cells
were stimulated with plate-coated anti-CD3 mAb for 24 hours.
The secretions of IL-2, IFN-c, IL-4, and IL-10 in the supernatants
were analyzed by ELISA as described in Method S1. Data are
means 6 SD of triplicates. *P,0.05, vs control.
(TIF)
Figure S5 Cytokine secretions from Ni-stimulated DCs. BMDCs
were stimulated with NiCl2, LPS, and TiO2 for 24 hours. The
cytokine secretions of IL-12, IFN-c, and IL-10 were detected by
ELISA as described in Method S1. Data are means 6 SD of
triplicates.
(TIF)
Methods S1
(DOCX)
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